You are here

STS101

Satsuma peels off staff, cutting head count by 36% to save cash while searching for a deal

Fierce Biotech

Wed, 03/29/23 - 09:37 am

Satsuma Pharmaceuticals

Satsuma in the red after 2nd phase 3 migraine flop spurs search for strategic alternatives

Fierce Biotech

Mon, 11/14/22 - 10:48 am

Satsuma Pharmaceuticals

clinical trials

intra-nasal drug delivery

Satsuma peels off fresh strip of long-term migraine study data ahead of planned FDA filing

Fierce Pharma

Mon, 09/26/22 - 10:57 am

Satsuma Pharmaceuticals

clinical trials

Satsuma Pharma's STS101 flunks late-stage migraine study, shares down 84%

Seeking Alpha

Thu, 09/10/20 - 10:23 am

Satsuma Pharmaceuticals

clinical trials

Satsuma Pharmaceuticals Files for $80 Million IPO

CP Wire

Thu, 09/12/19 - 10:25 am

Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Files for $80 Million IPO

Thu, 09/12/19 - 09:33 am

Satsuma Pharmaceuticals

Why Satsuma investors see room for another migraine therapy

BioCentury

Wed, 04/24/19 - 10:38 pm

Satsuma Pharmaceuticals

clinical trials